G. Kelly Martin

Mr. Martin is Chairman of Wren Therapeutics and has served in this position since 2018. Mr. Martin is currently Chief Executive Officer of Radius Health (Nasdaq: RDUS), a publicly quoted biopharmaceutical company committed to developing and commercializing innovative endocrine therapeutics. From 2003 to 2013, Mr. Martin was CEO of Elan Corporation plc, a pharmaceutical company focused on neurodegenerative diseases such as multiple sclerosis, Alzheimer’s, and Parkinson’s. Headquartered in Ireland, Elan operated globally and maintained several strategic partnerships including Biogen Idec and Johnson & Johnson. The company was sold to Perrigo Company plc in 2013 for more than $8.6 billion in stock and cash. Mr. Martin’s professional career started in finance having spent 22 years at Merrill Lynch & Co. Inc., leading several global divisions including Debt markets, International Equities, Systems & Technology, and the International Private Banking Group. While at Merrill Lynch, Mr. Martin lived and worked in New York, Tokyo, and London.